biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > No, zwerp2000 was not right

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jun 22, 2023 12:48pm

92 Views

Post# 35509460

RE:No, zwerp2000 was not right

xb3 is no good. the writing is on the wall. perhaps you can't accept that xb3 is no good because then that would invalidate everything you've said for years which is a tough pill to swallow. the company is shutting down. prothena passed on this company/ chiesi signed a deal and then eventually dropped bti which shows they did not see the utility of xb3 and no one else in biotech land came forward to even take a flyer on this technology. you were wrong....but your ego is too big to admit it. in the end, it does not matter. you wasted so many years of your life here talking about a biotech scam that never did anything other than lose shareholders money. you have nothing to show for this. sad.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale